GENINCODE PLC LS -01 (9PL) - Total Liabilities
Based on the latest financial reports, GENINCODE PLC LS -01 (9PL) has total liabilities worth €2.25 Million EUR (≈ $2.63 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GENINCODE PLC LS -01 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
GENINCODE PLC LS -01 - Total Liabilities Trend (2021–2025)
This chart illustrates how GENINCODE PLC LS -01's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GENINCODE PLC LS -01 assets under control.
GENINCODE PLC LS -01 Competitors by Total Liabilities
The table below lists competitors of GENINCODE PLC LS -01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tennant Minerals Ltd
AU:TMS
|
Australia | AU$299.10K |
|
Bloomsbury Publishing Plc
LSE:BMY
|
UK | GBX148.60 Million |
|
Woodlandor Holdings Bhd
KLSE:7025
|
Malaysia | RM6.95 Million |
|
TGS Esports Inc
V:TGS
|
Canada | CA$3.69 Million |
|
Riedel Resources Ltd
AU:RIE
|
Australia | AU$712.75K |
|
Duta Pertiwi Nusantara Tbk
JK:DPNS
|
Indonesia | Rp6.43 Billion |
|
Weststar Industrial Ltd
AU:WSI
|
Australia | AU$27.33 Million |
|
California Software Company Limited
NSE:CALSOFT
|
India | Rs-412.74 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down GENINCODE PLC LS -01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 9PL equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 18.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENINCODE PLC LS -01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENINCODE PLC LS -01 (2021–2025)
The table below shows the annual total liabilities of GENINCODE PLC LS -01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.25 Million ≈ $2.63 Million |
+46.68% |
| 2024-12-31 | €1.54 Million ≈ $1.80 Million |
-46.98% |
| 2023-12-31 | €2.90 Million ≈ $3.39 Million |
-25.66% |
| 2022-12-31 | €3.90 Million ≈ $4.56 Million |
+161.19% |
| 2021-12-31 | €1.49 Million ≈ $1.74 Million |
-- |
About GENINCODE PLC LS -01
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of fa… Read more